Payment overview · 2025
General Payments
$886.80
28 reported records · 19 companies
Healthcare provider profile · identity verified
Shagun Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · TUCSON, AZ · NPI 1730634346
Verified facts
What the public records show
CMS Open Payments records show Shagun Singh, M.D. received $886.80 in general payments during 2025 across 28 reported records.
Incyte Corporation accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Incyte Corporation | Unresolved — no canonical attribution shown | $172.87 | 19.5% | 4 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $135.00 | 15.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $115.11 | 13.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $72.58 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.87 | 6.1% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $45.46 | 5.1% | 2 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $42.66 | 4.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $26.54 | 3.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $25.50 | 2.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.86 | 2.7% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.26 | 2.6% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $21.64 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.71 | 2.3% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $20.59 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.77 | 2.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.43 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.34 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.86 | 1.9% | 1 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $686.82 | 26 |
| Education | $199.98 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Drug | AstraZeneca Pharmaceuticals LP | $115.11 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $54.57 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $42.66 | 1 | 2025 |
Source payment records
|
|||||
| LIVTENCITY Normalized: livtencity |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| ALTUVIIIO Normalized: altuviiio |
Biological | GENZYME CORPORATION | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| AKEEGA Normalized: akeega |
Drug | Janssen Biotech, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Biotech, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological | PFIZER INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 395 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 341 | 106 |
| Lisinopril | Lisinopril | 293 | 87 |
| Losartan Potassium | Losartan Potassium | 261 | 84 |
| Metformin Hcl | Metformin Hcl | 172 | 56 |
| Gabapentin | Gabapentin | 167 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 51 |
| Trazodone Hcl | Trazodone Hcl | 157 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 46 |
| Ozempic | Semaglutide | 130 | 22 |
| Omeprazole | Omeprazole | 126 | 44 |
| Simvastatin | Simvastatin | 110 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 26 |
| Montelukast Sodium | Montelukast Sodium | 77 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 18 |
| Metformin Hcl Er | Metformin Hcl | 55 | 19 |
| Alendronate Sodium | Alendronate Sodium | 54 | 17 |
| Bupropion Xl | Bupropion Hcl | 54 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 18 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Eliquis | Apixaban | 48 | 11 |
| Meloxicam | Meloxicam | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 12 |
| Estradiol | Estradiol | 39 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 18 |
| Carvedilol | Carvedilol | 38 | 17 |
| Famotidine | Famotidine | 38 | 16 |
| Telmisartan | Telmisartan | 37 | 16 |
| Baclofen | Baclofen | 36 | 13 |
| Furosemide | Furosemide | 35 | 17 |
| Mirtazapine | Mirtazapine | 34 | 13 |
| Potassium Chloride | Potassium Chloride | 34 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Allopurinol | Allopurinol | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 12 |
| Ezetimibe | Ezetimibe | 30 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 19 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Methocarbamol | Methocarbamol | 21 | 12 |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Yuvafem | Estradiol | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Prednisone | Prednisone | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $886.80 · 28 records | Incyte Corporation | AKEEGA, ALTUVIIIO, AYVAKIT, BALVERSA, DARZALEX, Da Vinci Surgical System, ERLEADA, FOTIVDA, IBRANCE, JAKAFI, KEYTRUDA, LIVTENCITY, LYNPARZA, Lenvima, MONJUVI, NIKTIMVO, Nubeqa, OJJAARA, ORGOVYX, PADCEV, QINLOCK, ROMVIMZA, RYTELO, SCEMBLIX, Stivarga, TALZENNA, TECVAYLI, TUKYSA, Trodelvy, Vanflyta, Vitrakvi, Vonjo, WELIREG, XTANDI, ZYNYZ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error